Clinical trials: EGFR DEL19
Non-Small Cell Lung Cancer
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
This is a Phase 1/2 study of PF-06747775 as a single agent and in combination with other cancer treatments in patients with advanced EGFRm NSCLC.
- Trial name
- NCT02349633
- Testing
- PF-06747775, Palbociclib, Avelumab
- Where
- 15 sites in United States, Australia and 2 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer, EGFR Activating Mutation
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
IFCT-2202 ROSIE study aims to incorporate a broad-panel centralized NGS testing at baseline in all patients with completely resected NSCLC with common EGFR mutation after confirmation of an optimal preoperative extension…
- Conditions
- Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
- Trial name
- ROSIE (NCT06053099)
- Testing
- Plasma ctDNA, FFPE blocks
- Where
- 36 sites in France
- Volunteers
- 300 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Locally Advanced or Metastatic Non-small Cell Lung Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This study is a multicenter, single arm, open label, phase I clinical trial, including dose escalation (phase IA) and dose expansion (phase IB).
- Trial name
- NCT06955988
- Testing
- AST2303 Tablets(ABK3376 Tablets) ，25mg, AST2303 Tablets(ABK3376 Tablets) ，50mg, AST2303 Tablets(ABK3376 Tablets) ，75mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Allist Pharmaceuticals, Inc.
EGFR Exon 19 Mutation, Tumor Progression
Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants
To determine the optimal EGFR TKIs treatment strategies for lung adenocarcinoma harboring EGFR exon 19 deletion variants
- Trial name
- NCT04370860
- Where
- Taiwan
- Volunteers
- 1,000 people
- Sponsor
- National Taiwan University Hospital
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Carcinoma, Non-Small-Cell Lung
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
The objectives of this single-arm, open-label trial are to assess the efficacy and safety of afatinib as second line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring a…
- Trial name
- NCT02208843
- Testing
- Afatinib
- Where
- 21 sites in Egypt, Malaysia and 5 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer
Phase 1 - open label, multi-center, non-randomized, safety, pharmacokinetic and pharmacodynamics dose escalation study of PF-06459988 as a single agent in patients with advance EGFRm NSCLC (del 19, L858R, +/- T790M).
- Trial name
- NCT02297425
- Testing
- PF-06459988
- Sponsor
- Pfizer